Assessing TCR identity, knock-in efficiency, and potency for individualized TCR-T cell therapy.

[1]  Patricia A. Young,et al.  CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma , 2022, medRxiv.

[2]  Yangqiu Li,et al.  TCR engineered T cells for solid tumor immunotherapy , 2022, Experimental Hematology & Oncology.

[3]  S. Rutz,et al.  High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNA , 2022, The Journal of experimental medicine.

[4]  Melissa A. Wilson,et al.  Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation , 2022, Frontiers in Oncology.

[5]  U. Şahin,et al.  Ribozyme Assays to Quantify the Capping Efficiency of In Vitro-Transcribed mRNA , 2022, Pharmaceutics.

[6]  Yumin Li,et al.  TCR-T Immunotherapy: The Challenges and Solutions , 2022, Frontiers in Oncology.

[7]  A. Kamb,et al.  Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers , 2021, Journal of immunotherapy.

[8]  Nikola A. Ivica,et al.  Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020) , 2021, Healthcare.

[9]  A. Harari,et al.  The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients , 2021, Frontiers in Immunology.

[10]  J. Gartner,et al.  Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing , 2021, Journal for ImmunoTherapy of Cancer.

[11]  O. Casasnovas,et al.  Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients , 2021, Journal of translational medicine.

[12]  Peiwen J. Ma,et al.  Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors , 2021, BMC Medicine.

[13]  Rosalie M Sterner,et al.  CAR-T cell therapy: current limitations and potential strategies , 2021, Blood Cancer Journal.

[14]  C. Cho,et al.  Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons , 2021, Frontiers in Immunology.

[15]  M. Houston,et al.  Cap 1 Messenger RNA Synthesis with Co‐transcriptional CleanCap® Analog by In Vitro Transcription , 2021, Current protocols.

[16]  A. Nekrutenko,et al.  Sequencing error profiles of Illumina sequencing instruments , 2021, NAR genomics and bioinformatics.

[17]  Michael S. Rooney,et al.  Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1 , 2020, Cell reports. Medicine.

[18]  Alexander V Gopanenko,et al.  Main Strategies for the Identification of Neoantigens , 2020, Cancers.

[19]  Leila Haery,et al.  A Novel Next-Generation Sequencing and Analysis Platform to Assess the Identity of Recombinant Adeno-Associated Viral Preparations from Viral DNA Extracts , 2020, Human gene therapy.

[20]  Zonghai Li,et al.  Genetically engineered T cells for cancer immunotherapy , 2019, Signal Transduction and Targeted Therapy.

[21]  Jia Wei,et al.  Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. , 2019, The Journal of clinical investigation.

[22]  J. Gartner,et al.  Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer , 2019, Cancer Immunology Research.

[23]  J. Gartner,et al.  Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. , 2018, JCI insight.

[24]  A. Pritchard,et al.  Identifying neoantigens for use in immunotherapy , 2018, Mammalian Genome.

[25]  Omkar U. Kawalekar,et al.  CAR T cell immunotherapy for human cancer , 2018, Science.

[26]  M. Beverly,et al.  Poly A tail length analysis of in vitro transcribed mRNA by LC-MS , 2018, Analytical and Bioanalytical Chemistry.

[27]  K. Flaherty,et al.  Mechanisms of resistance to immune checkpoint inhibitors , 2018, British Journal of Cancer.

[28]  B. Badie,et al.  Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications , 2017, Front. Immunol..

[29]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[30]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[31]  M. Disis,et al.  Clinical significance of tumor-infiltrating lymphocytes in breast cancer , 2016, Journal of Immunotherapy for Cancer.

[32]  M. Beverly,et al.  Label-free analysis of mRNA capping efficiency using RNase H probes and LC-MS , 2016, Analytical and Bioanalytical Chemistry.

[33]  T. Wittkop,et al.  Multiplex Identification of Antigen-Specific T Cell Receptors Using a Combination of Immune Assays and Immune Receptor Sequencing , 2015, PloS one.

[34]  Kin-Fan Au,et al.  PacBio Sequencing and Its Applications , 2015, Genom. Proteom. Bioinform..

[35]  J. Gartner,et al.  Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. , 2015, The Journal of clinical investigation.

[36]  Maxim N. Artyomov,et al.  Tumor neoantigens: building a framework for personalized cancer immunotherapy. , 2015, The Journal of clinical investigation.

[37]  Bent K Jakobsen,et al.  Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  Bing Yu,et al.  Somatic DNA mutation analysis in targeted therapy of solid tumours. , 2015, Translational pediatrics.

[39]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[40]  T. Blankenstein,et al.  Targeting cancer-specific mutations by T cell receptor gene therapy. , 2015, Current opinion in immunology.

[41]  Z. Modrušan,et al.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.

[42]  A. Sewell,et al.  Comparison of peptide–major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells , 2014, Clinical and experimental immunology.

[43]  F. Dammacco,et al.  MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. , 2013, Journal of the National Cancer Institute.

[44]  Adam Bagg,et al.  Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. , 2013, Blood.

[45]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[46]  A. Sewell,et al.  Peptide length determines the outcome of TCR/peptide-MHCI engagement. , 2013, Blood.

[47]  Pia Kvistborg,et al.  The cancer antigenome , 2012, The EMBO journal.

[48]  Neil Hall,et al.  Advanced sequencing technologies and their wider impact in microbiology , 2007, Journal of Experimental Biology.

[49]  S. Rosenberg,et al.  Adoptive T-Cell Therapy for Cancer. , 2016, Advances in immunology.

[50]  C. Cohen,et al.  Adoptive T-Cell Immunotherapy: Perfecting Self-Defenses , 2014 .